Maternal use of selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn

Clinical Pharmacology and Therapeutics

Volumn 100, Issue 1, 2016, Pages 34-41

  Alwan, S ^a   Bandoli, G ^b   Chambers, C D ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; COHORT ANALYSIS; DISEASE ASSOCIATION; HUMAN; INFANT MORTALITY; MATERNAL EXPOSURE; MEDLINE; NEWBORN; NEWBORN DISEASE; NEWBORN MORBIDITY; PERSISTENT PULMONARY HYPERTENSION; PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN; PRIORITY JOURNAL; PROSPECTIVE STUDY; THIRD TRIMESTER PREGNANCY; COMPLICATION; DEPRESSION; FEMALE; PATHOPHYSIOLOGY; PERSISTENT FETAL CIRCULATION SYNDROME; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE; RISK FACTOR;

DEPRESSION; FEMALE; HUMANS; INFANT, NEWBORN; PERSISTENT FETAL CIRCULATION SYNDROME; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS;

EID: 84966659553     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.376     Document Type: Article

References (60)

1. Puthiyachirakkal, M. & Mhanna, M.J. Pathophysiology, management, and outcome of persistent pulmonary hypertension of the newborn: a clinical review. Front. Pediatr. 1, 23 (2013).
2. Konduri, G.G. & Kim, U.O. Advances in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatr. Clin. North Am. 56, 579-600 (2009).
3. Farrow, K.N., Fliman, P. & Steinhorn, R.H. The diseases treated with ECMO: focus on PPHN. Semin. Perinatol. 29, 8-14 (2005).
4. Eriksen, V., Nielsen, L.H., Klokker, M. & Greisen, G. Follow-up of 5- to 11-year-old children treated for persistent pulmonary hypertension of the newborn. Acta Paediatr. 98, 304-309 (2009).
5. Ostrea, E.M., Villanueva-Uy, E.T., Natarajan, G. & Uy, H.G. Persistent pulmonary hypertension of the newborn: pathogenesis, etiology, and management. Paediatr. Drugs 8, 179-188 (2006).
6. Hernandez-Diaz, S., Van, Marter L.J., Werler, M.M., Louik, C. & Mitchell, A.A. Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics 120, e272-e282 (2007).
7. Hansen, A.K., Wisborg, K., Uldbjerg, N. & Henriksen, T.B. Risk of respiratory morbidity in term infants delivered by elective caesarean section: cohort study. BMJ. 336, 85-87 (2008).
8. Wilson, K.L. et al. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am. J. Perinatol. 28, 19-24 (2011).
9. Reece, E.A. et al. Persistent pulmonary hypertension: assessment of perinatal risk factors. Obstet. Gynecol. 70, 696-700 (1987).
10. Huybrechts, K.F. et al. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA. 313, 2142-2151 (2015).
11. Reis, M. & Kallen, B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol. Med. 40, 1723-1733 (2010).
12. Storme, L. et al. Pathophysiology of persistent pulmonary hypertension of the newborn: impact of the perinatal environment. Arch. Cardiovasc. Dis. 106, 169-177 (2013).
13. Van Marter, L.J. et al. Persistent pulmonary hypertension of the newborn and smoking and aspirin and nonsteroidal antiinflammatory drug consumption during pregnancy. Pediatrics 97, 658-663 (1996).
14. Van Marter, L.J., Hernandez-Diaz, S., Werler, M.M., Louik, C. & Mitchell, A.A. Nonsteroidal antiinflammatory drugs in late pregnancy and persistent pulmonary hypertension of the newborn. Pediatrics 131, 79-87 (2013).
15. Alano, M.A., Ngougmna, E., Ostrea, E.M., Jr. & Konduri, G.G. Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics 107, 519-523 (2001).
16. Alwan, S., Reefhuis, J., Rasmussen, S.A. & Friedman, J.M. Patterns of antidepressant medication use among pregnant women in a United States population. J. Clin. Pharmacol. 51, 264-270 (2011).
17. Andrade, S.E. et al. Use of antidepressant medications during pregnancy: a multisite study. Am. J. Obstet. Gynecol. 198, 194e1-5 (2008).
18. Huybrechts, K.F. et al. National trends in antidepressant medication treatment among publicly insured pregnant women. Gen. Hosp. Psychiatry 35, 265-271 (2013).
19. Chambers, C.D. et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N. Engl. J. Med. 354, 579-587 (2006).
20. US Food and Drug Administration. Public health advisory: treatment challenges of depression in pregnancy and the possibility of persistent pulmonary hypertension in newborns.
21. Archive-Newer antidepressants linked to serious lung disorder in newborns 2013. .
22. Andrade, S.E. et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol. Drug Saf. [Research Support, U.S. Gov't, P.H.S.]. 18, 246-252 (2009).
23. Wichman, C.L. et al. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin. Proc. [Comparative Study]. 84, 23-27 (2009).
24. US Food and Drug Administration. FDA Drug Safety Communication: Selective serotonin reuptake inhibitor (SSRI) antidepressant use during pregnancy and reports of a rare heart and lung condition in newborn babies. (2012).
25. Galbally, M., Gentile, S. & Lewis, A.J. Further findings linking SSRIs during pregnancy and persistent pulmonary hypertension of the newborn: clinical implications. CNS Drugs 26, 813-822 (2012).
26. Occhiogrosso, M., Omran, S.S. & Altemus, M. Persistent pulmonary hypertension of the newborn and selective serotonin reuptake inhibitors: lessons from clinical and translational studies. Am. J. Psychiatry 169, 134-140 (2012).
27. Grigoriadis, S. et al. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. BMJ. 348, f6932 (2014).
28. Chambers, C.D., Johnson, K.A., Dick, L.M., Felix, R.J. & Jones, K.L. Birth outcomes in pregnant women taking fluoxetine. N. Engl. J. Med. 335, 1010-1015 (1996).
29. Greenland, S., Pearl, J. & Robins, J.M. Causal diagrams for epidemiologic research. Epidemiology 10, 37-48 (1999).
30. Hallberg, P., Odlind, V. & Sjoblom, V. Selective serotonin-reuptake inhibitors and persistent pulmonary hypertension of the newborn. N. Engl. J. Med. 354, 2188-2190; author reply 2190 (2006).
31. Kallen, B. & Olausson, P.O. Maternal use of selective serotonin reuptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol. Drug Saf. 17, 801-806 (2008).
32. Kieler, H. et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. [Multicenter Study Research Support, Non-U.S. Gov't]. BMJ. 344, d8012 (2012).
33. Kallen, B., Nilsson, E. & Olausson, P.O. Antidepressant use during pregnancy: comparison of data obtained from a prescription register and from antenatal care records. Eur. J. Clin. Pharmacol. 67, 839-845 (2011).
34. Fornaro, E., Li, D., Pan, J. & Belik J. Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat. Am. J. Respir. Crit. Care Med. 176, 1035-1040 (2007).
35. Lim, K. et al. Third trimester fetal pulmonary artery Doppler blood flow velocity characteristics following prenatal selective serotonin reuptake inhibitor (SSRI) exposure. Early Hum. Dev. 88, 609-615 (2012).
36. Davis, R.L. et al.; HMO Research Network Center for Education, Research in Therapeutics. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol. Drug Saf. 16, 1086-1094 (2007).
37. Costei, A.M., Kozer, E., Ho, T., Ito, S. & Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch. Pediatr. Adolesc. Med. 156, 1129-1132 (2002).
38. Oberlander, T.F., Warburton, W., Misri, S., Aghajanian, J. & Hertzman, C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch. Gen. Psychiatry 63, 898-906 (2006).
39. Kallen, B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch. Pediatr. Adolesc. Med. 158, 307-308 (2004).
40. Casper, R.C. et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J. Pediatr. 142, 402-408 (2003).
41. Pollock, B.G. et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 23, 587-590 (2000).
42. Oberlander, T.F. et al. Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol. Psychiatry 13, 65-73 (2008).
43. Field, T.D.M. & Hernandez-Reif, M. Prenatal depression effects on the fetus and newborn: a review. Infant Behav. Dev. 29, 445-455 (2006).
44. Orr, S.T. & Miller, C.A. Maternal depressive symptoms and the risk of poor pregnancy outcome. Review of the literature and preliminary findings. Epidemiol. Rev. 17, 165-171 (1995).
45. Chung, T.K., Lau, T.K., Yip, A.S., Chiu, H.F. & Lee, D.T. Antepartum depressive symptomatology is associated with adverse obstetric and neonatal outcomes. Psychosom. Med. 63, 830-834 (2001).
46. Grote, N.K. et al. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch. Gen. Psychiatry 67, 1012-1024 (2010).
47. Hobel, C.J., Goldstein, A. & Barrett, E.S. Psychosocial stress and pregnancy outcome. Clin. Obstet. Gynecol. 51, 333-348 (2008).
48. Hanley, G.E. & Oberlander, T.F. The effect of perinatal exposures on the infant: antidepressants and depression. Best Pract. Res. Clin. Obstet. Gynaecol. 28, 37-48 (2014).
49. Maschi, S. et al. Neonatal outcome following pregnancy exposure to antidepressants: a prospective controlled cohort study. BJOG. 115, 283-289 (2008).
50. Giannakopoulos, G. Maternal antidepressant use and persistent pulmonary hypertension of the newborn. JAMA. 314, 1293-1294 (2015).
51. Huybrechts, K.F., Bateman, B.T. & Hernandez-Diaz, S. Maternal antidepressant use and persistent pulmonary hypertension of the newborn-reply. JAMA. 314, 1294 (2015).
52. Cohen, L.S. et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 295, 499-507 (2006).
53. Walsh-Sukys, M.C. et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 105(1 Pt 1), 14-20 (2000).
54. Simon, G.E., Cunningham, M.L. & Davis, R.L. Outcomes of prenatal antidepressant exposure. Am. J. Psychiatry 159, 2055-2061 (2002).
55. Wen, S.W. et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am. J. Obstet. Gynecol. 194, 961-966 (2006).
56. Pearson, K.H. et al. Birth outcomes following prenatal exposure to antidepressants. J. Clin. Psychiatry 68, 1284-1289 (2007).
57. Malm, H., Klaukka, T. & Neuvonen, P.J. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet. Gynecol. 106, 1289-1296 (2005).
58. Cohen, L.S. et al. Birth outcomes following prenatal exposure to fluoxetine. Biol. Psychiatry 48, 996-1000 (2000).
59. Hendrick, V. et al. Placental passage of antidepressant medications. Am. J. Psychiatry 160, 993-996 (2003).
60. Levinson-Castiel, R., Merlob, P., Linder, N., Sirota, L. & Klinger, G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch. Pediatr. Adolesc. Med. 160, 173-176 (2006).